Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
EIF2S2 Rabbit anti-Human, Mouse, Polyclonal, Proteintech

Rabbit Polyclonal Antibody
Supplier: Proteintech Group Inc 102271AP150UL

Description
Transcriptional coactivator for CREB1 which activates transcription through both consensus and variant cAMP response element (CRE) sites. Acts as a coactivator, in the SIK/TORC signaling pathway, being active when dephosphorylated and acts independently of CREB1 ′Ser-133′ phosphorylation. Enhances the interaction of CREB1 with TAF4. Regulates the expression of specific CREB-activated genes such as the steroidogenic gene, StAR. Potent coactivator of PPARGC1A and inducer of mitochondrial biogenesis in muscle cells. Also coactivator for TAX activation of the human T-cell leukemia virus type 1 (HTLV-1) long terminal repeats (LTR). Tissue specificity: Predomitly expressed in B and T lymphocytes. Highest levels in lung. Also expressed in brain, colon, heart, kidney, ovary, and prostate. Weak expression in liver, pancreas, muscle, small intestine, spleen and stomach.Specifications
EIF2S2 | |
Polyclonal | |
Unconjugated | |
EIF2S2 | |
eIF 2 beta, EIF2, EIF2B, EIF2beta, EIF2S2 | |
Rabbit | |
Antigen Affinity Chromatography | |
RUO | |
67204, 8894 | |
-20°C | |
Liquid |
Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot | |
0.25 mg/mL | |
PBS with 50% glycerol and 0.1% sodium azide; pH 7.3 | |
P20042, Q99L45 | |
EIF2S2 | |
EIF2S2 Fusion Protein Ag0269 | |
150 μL | |
Primary | |
Human, Mouse | |
Antibody | |
IgG |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction